GTCR commits up to $200m for 2nd Fiorentino-led venture
This article was originally published in Scrip
The private equity firm GTCR is placing another bet with Ed Fiorentino by investing up to $200 million in the newly formed Crealta Pharmaceuticals, which will acquire assets and companies hand-picked by Fiorentino and his team.
You may also be interested in...
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Expanding on difficult conversations during the recent BIO Digital meeting, the group aims to take actions that will increase diversity and inclusion in health care, science and industry.
Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma.